Was Blake Borgeson’s RXRX share sale made under a Rule 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. The footnote states the transaction followed a trading plan adopted by Blake Borgeson on August 31, 2025, indicating the sale was pre-arranged rather than a discretionary, spur-of-the-moment trade.

What was the price per share in Blake Borgeson’s recent RXRX stock sale?

The reported transaction price was $3.68 per share for Recursion Pharmaceuticals Class A Common Stock. All 30,000 shares in the Form 4 were sold at this price in an open-market sale, as disclosed in the non-derivative transaction section of the filing.

Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Blake Borgeson sold shares in a planned trade. On June 2, he executed an open-market sale of 30,000 shares of Class A Common Stock at $3.68 per share. After the sale, he directly holds 6,169,863 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 31, 2025.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares ($110,400)

Net Sell 1 txn

Insider Borgeson Blake

Role null

Sold 30,000 shs ($110K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	30,000	$3.68	$110K

Holdings After Transaction: Class A Common Stock — 6,169,863 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 30,000 shares Sale price per share: $3.68 per share Shares owned after transaction: 6,169,863 shares +1 more

4 metrics

Shares sold 30,000 shares Class A Common Stock sold in open-market transaction on June 2

Sale price per share $3.68 per share Price for the 30,000 Class A shares sold

Shares owned after transaction 6,169,863 shares Director’s direct Class A Common Stock holdings following the sale

Transaction code S Denotes open-market or private sale of non-derivative securities

Key Terms

Rule 10b5-1 trading plan, Class A Common Stock, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 05:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/02/2026		S⁽¹⁾		30,000	D	$3.68	6,169,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Blake Borgeson report at Recursion Pharmaceuticals (RXRX)?

Blake Borgeson reported an open-market sale of Recursion Pharmaceuticals shares. He sold 30,000 shares of Class A Common Stock at $3.68 per share on June 2 under a pre-established Rule 10b5-1 trading plan, according to the Form 4 filing.

How many Recursion Pharmaceuticals (RXRX) shares did Blake Borgeson retain after the sale?

After the reported sale, Blake Borgeson directly holds 6,169,863 shares of Recursion Pharmaceuticals Class A Common Stock. This figure in the Form 4 shows his remaining direct ownership position immediately following the 30,000-share open-market transaction disclosed in the filing.

What type of transaction did the RXRX Form 4 report for Blake Borgeson?

The Form 4 reports an open-market sale of non-derivative securities. Specifically, it lists a sale (transaction code “S”) of 30,000 shares of Class A Common Stock, executed directly by Blake Borgeson, rather than through derivative instruments or indirect ownership structures.